Compounded tirzepatide vs Zepbound and Mounjaro: status and price
By the Tirzepatide Price data desk · Article updated 20 Nov 2026 · Prices checked 21 Nov 2026
What each one is
Zepbound is Eli Lilly's brand of tirzepatide. Its label says it is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity (label).
Mounjaro is the same company's tirzepatide brand for type 2 diabetes. Its label says it is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events (label).
Compounded tirzepatide is prepared by a pharmacy or an outsourcing facility, not by Lilly (FDA, page current as of 1 October 2026).
FDA status and timeline
Pharmacies could compound tirzepatide at scale while it was on the FDA's shortage list. That allowance has ended.
| Date | What happened |
|---|---|
| 2 Oct 2024 | The FDA finds the tirzepatide shortage resolved, and confirms it on 19 December 2024 after a court remand (FDA). |
| 18 Feb 2025 | The grace period for state-licensed pharmacies under section 503A was set to end, pending a court challenge. On 5 March 2025 the district court denied an injunction and the FDA said the period had ended (FDA). |
| 19 Mar 2025 | The grace period for outsourcing facilities under section 503B ends (FDA). |
| 3 Mar 2026 | The FDA announces 30 warning letters, dated 20 February, to telehealth companies over false or misleading claims about compounded GLP-1 products (FDA). One went to SkinnyRx. |
| 1 Apr 2026 | The FDA restates the rules. A 503A pharmacy may not make essentially a copy of a commercially available drug regularly or in inordinate amounts. Four or fewer such prescriptions a month fall below the FDA's threshold for action. A 503B facility needs the substance to be on the 503B bulks list or the shortage list, and tirzepatide is on neither (FDA). |
| 7 Apr 2026 | Warning letter to ProRx, a 503B facility. Letters follow to OrderlyMeds on 8 June and Empower Pharmacy on 18 September. |
| 1 May 2026 | The FDA proposes not to include tirzepatide on the 503B bulks list. Comments closed on 30 June (Federal Register). |
| 27 Aug 2026 | The Fifth Circuit rules for the FDA in Outsourcing Facilities Association v. FDA, No. 25-10600, the challenge to the end of the tirzepatide shortage (opinion). |
What it means for buyers
Sellers still advertise compounded tirzepatide, and we list 17 of them. The rules leave less room than they did. A 503A pharmacy can compound for an identified patient when the prescriber documents a change that makes a significant difference for that patient. In its letter to Empower Pharmacy, the FDA objected to identical “significant difference” notes repeated across many records (letter).
- Supply can change. A seller listed today may change its product or stop selling it.
- As of 31 May 2026 the FDA had received more than 730 reports of adverse events associated with compounded tirzepatide. It notes that it cannot always tell whether the drug caused the event (FDA).
- Doses differ, so a price may not compare dose for dose. Mochi Health lists weekly doses from 2.2 mg to 16.6 mg, not the six strengths on the Zepbound label (Mochi, checked 21 Nov 2026).
This page reports prices and rules. It is not medical advice, and we do not recommend any drug, dose, pharmacy or prescriber. Tirzepatide is a prescription medicine. Talk to a licensed clinician before starting, changing or stopping treatment, and read the FDA-approved label, including the boxed warning.
The price gap by dose
The table shows the lowest all-in price per 4 weeks in each group, with membership included. Readings we rate low-confidence are left out.
| Dose | Lowest FDA-approved | Lowest compounded, not FDA-approved | Gap |
|---|---|---|---|
| 2.5 mg | $299LillyDirect | $128Biotech Lifestyle | $171 less |
| 5 mg | $399LillyDirect | $140Biotech Lifestyle | $259 less |
| 10 mg | $449LillyDirect | $159Biotech Lifestyle | $290 less |
| 15 mg | $449LillyDirect | $184Biotech Lifestyle | $265 less |
Prices checked 21 Nov 2026. Of the 17 compounded offers we list, 9 publish a price that applies at 15 mg. The rest publish a starting or first-month figure only. Lilly's price from 7.5 mg up assumes a refill within 45 days. See every row on compounded tirzepatide prices and Zepbound prices.
What we do not know
The FDA has not, as far as we could find on 20 Nov 2026, published a final decision on its May 2026 proposal to keep tirzepatide off the 503B bulks list. We also do not know whether the Fifth Circuit ruling will be taken further, or how many sellers will keep offering compounded tirzepatide.
Common questions
Is compounded tirzepatide FDA-approved?
No. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. Zepbound and Mounjaro are the FDA-approved tirzepatide products.
Why is compounded tirzepatide still sold?
The shortage allowance has ended, but section 503A still lets a pharmacy compound for an identified patient in limited circumstances. The FDA's 1 April 2026 statement sets out those limits. We do not assess whether any one seller meets them.
Sources
Checked 20 Nov 2026.
- Zepbound prescribing information (FDA-approved label), Eli Lilly, revised November 2026
- Mounjaro prescribing information (FDA-approved label), Eli Lilly, revised November 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, content current as of 1 April 2026
- FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026
- FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, 3 March 2026
- FDA warning letter to Lean Rx, Inc. dba SkinnyRx, 20 February 2026
- FDA warning letter to ProRx LLC, 7 April 2026
- FDA warning letter to OrderlyMeds LLC, 8 June 2026
- FDA warning letter to Empower Clinic Services LLC dba Empower Pharmacy, 18 September 2026
- Federal Register notice 2026-08552 on the section 503B bulk drug substances list, published 1 May 2026
- Outsourcing Facilities Association v. FDA, No. 25-10600 (5th Cir. 27 August 2026), opinion